Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy

SIMPLE SUMMARY: Classic Hodgkin lymphoma (cHL) has a high cure rate with chemotherapy, but 10–30% of patients experience relapse or refractory (R/R) disease, depending on stage and risk factors. Treatment for R/R cHL differs between young, fit patients who are eligible for high-dose chemotherapy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Randall, Michael P., Spinner, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526852/
https://www.ncbi.nlm.nih.gov/pubmed/37760478
http://dx.doi.org/10.3390/cancers15184509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526852/
https://www.ncbi.nlm.nih.gov/pubmed/37760478
http://dx.doi.org/10.3390/cancers15184509

Ejemplares similares